Abstract: 【Abstract】 Immune checkpoint inhibitors （ICIs） have become an important treatment option for many patients with malignant melanoma in the past few years. ICIs can restore and promote the function of effector T cells to specifically recognize and kill tumor cells, and systemically enhance anti-tumor immune response of the body, so they are a good treatment option for patients who have a high risk of recurrence after surgery or are at an advanced stage of disease （unresectable or metastatic melanoma）. The main targets of current ICIs are programmed death receptor 1 and cytotoxic T lymphocyte-associated antigen 4, which are two key receptors for central and peripheral immune tolerance respectively. This review mainly discusses clinical efficacy of different ICIs, possible biomarkers of response to ICIs and ICI-related adverse reactions.

Key words: Nevi and melanomas, Immune checkpoint, Programmed cell death 1 receptor, CTLA-4 antigen, Biomarkers, pharmacological, Drug toxicity, Immune checkpoint inhibitors